Boston Scientific Corporation and University of Rochester Medical Center announced that the MADIT-CRT trial has met its primary endpoint. New York Heart Association’s Class I and II patients were enrolled in this MADIT-CRT. It is observed that Boston Scientific cardiac resynchronization therapy defibrillators (CRT-Ds) reduce death or heart failure by 29 percent when compared to traditional implantable cardioverter defibrillators (ICDs). The executive committee of MADIT-CRT is expecting to present and publish the trial's full results later this year.
Boston Scientific through this MADIT-CRT demonstrated that early intervention with cardiac resynchronization therapy slows down the progression of heart failure. More than 1,800 patients at 110 centers in 14 countries are enrolled in this world’s largest randomized NYHA Class I/II MADIT-CRT trail.The trial is being conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester Medical Center.
We are very encouraged by these initial positive results, and we are hopeful they will eventually lead to a wider population of heart failure patients being treated with CRT-D therapy, said Fred Colen, President, Boston Scientific CRM. I would like to congratulate Dr. Moss, the Executive Committee and all the MADIT-CRT investigators on a well designed and well executed clinical trial. Boston Scientific is proud to continue the tradition of supporting advances in indications in the CRM space through trials like MADIT-CRT. More than 80 percent of US patients who receive an ICD or CRT-D were first indicated for this therapy by a clinical trial sponsored by Boston Scientific or its predecessors.
MADIT-CRT providing insight into the potential of CRT-D therapy to intervene earlier in the natural progression of heart failure. At present patients must be in NYHA Class III/IV heart failure to be indicated for CRT-D therapy. In US approximately 70 percent of all heart failure patients fall into Class I or II.